Mosaic ImmunoEngineering Development

Mosaic ImmunoEngineering is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company utilizes a proprietary plant virus-based nanotechnology platform, specifically the Cowpea Mosaic Virus (CPMV), to create in situ vaccines that stimulate the immune system to target and destroy tumors. By injecting these nanoparticles directly into a tumor, Mosaic aims to convert the local immunosuppressive environment into an immunostimulatory one, triggering a systemic anti-tumor response. The lead candidate, MIE-101, is currently being evaluated in clinical trials for various solid tumors, both as a monotherapy and in combination with checkpoint inhibitors. This approach leverages the natural immunogenicity of the plant virus to activate multiple Toll-like receptors and recruit immune cells to the tumor site.